Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

GLTO 10.15.2024

Full Press ReleaseSEC FilingsOur GLTO Tweets

About Gravity Analytica

Recent News

  • 11.01.2024 - Galecto Reports Third Quarter 2024 Financial Results
  • 10.15.2024 - Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Recent Filings

  • 01.16.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
  • 01.07.2025 - 4 Statement of changes in beneficial ownership of securities
  • 11.07.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
PDF Version

BOSTON,Oct. 15, 2024(GLOBE NEWSWIRE) --Galecto, Inc.(NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr.Amy Wechslerto its Board of Directors.Dr. Wechslerbrings a unique combination of expertise and a proven track record of leadership in the healthcare industry.

“We are thrilled to welcomeDr. Wechslerto our Board of Directors,” said Dr.Carl Goldfischer, Chair of the Board ofGalecto. “Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important addition to our team as we develop novel cancer and liver treatments. We look forward to her strategic insights and contributions.”

Dr. Wechsleris board-certified in both dermatology and psychiatry and has been a practicing dermatologist since 2005. Since 2016, she has served on the Board of Directors for Bausch Health where she played a key role in supporting the company through a successful IPO.Dr. Wechsleris also an adjunct clinical professor of psychiatry atWeill Cornell Medical College. She received a B.S. in psychology,magna cum laude, Phi Beta Kappa, fromDuke Universityand earned her M.D.,Alpha Omega Alpha, fromCornell University Medical College.Dr. Wechsleralso received her M.B.A. fromColumbia Business Schoolin 2024.

Dr. Wechslercommented, “I am honored to join the Galecto Board at this exciting time in the Company’s evolution as they expand their oncology pipeline. I look forward to contributing to Galecto’s mission to develop novel cancer and liver disease treatments and to collaborating with the management team and fellow Board members."

AboutGalectoGalectois a clinical-stage biopharmaceutical company committed to realizing the promise of novel treatments for cancer and liver diseases. The Company’s pipeline consists of first-in-class small molecule drug candidates that target cancer and fibrosis signaling pathways, including (i) an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis; (ii) an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications; and (iii) as recently announced, a preclinical dual inhibitor of ENL-YEATS and FLT3 (BRM-1420) for multiple genetic subsets of AML, whichGalectoacquired from Bridge Medicines.Galectointends to use its website as a means of disclosing material non-public information. For regular updates aboutGalecto, visitwww.galecto.com.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galecto’s focus and plans for preclinical and clinical development of its product candidates and pipeline. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements,Galectoclaims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially fromGalecto'sexpectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties related to the development of Galecto’s product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galecto’s filings with theSecurities and Exchange Commission(SEC), including, but not limited to, Galecto’s Annual Report on Form 10-K, as filed with theSEConMarch 8, 2024. These forward-looking statements representGalecto'sjudgment as of the time of this release.Galectodisclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

For more information, contact:

Investors/USMedia/EU
Ashley R. Robinsonarr@lifesciadvisors.comSandya von der Weidsvonderweid@lifesciadvisors.com
+1 617 430 7577+41 78 680 0538

Primary Logo

Source: Galecto, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com